Crystal polymorphism in chemical process development.
暂无分享,去创建一个
[1] D. Fox. Physics and Chemistry of the Organic Solid State , 1963 .
[2] Polymorphie bei Arzneistoffen , 1975 .
[3] S. Byrn. Solid state chemistry of drugs , 1982 .
[4] R. Davey,et al. The kinetics of solvent-mediated phase transformations , 1985, Proceedings of the Royal Society of London. A. Mathematical and Physical Sciences.
[5] S. Görög,et al. The polymorphism of cimetidine. , 1985, Journal of pharmaceutical and biomedical analysis.
[6] T. Matsubara,et al. Pseudo-polymorphism and crystalline transition of magnesium stearate , 1992 .
[7] A. P. Lötter,et al. Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide , 1992 .
[8] A. P. Lötter,et al. Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin , 1993 .
[9] P. York,et al. Dehydration of theophylline monohydrate powder — effects of particle size and sample weight , 1994 .
[10] A. P. Lötter,et al. Hydration of drug molecules: cavityinclusion of water in crystals of loperamide hydrochloride tetrahydrate , 1995 .
[11] Gregory A. Stephenson,et al. Purification of Dirithromycin. Impurity Reduction and Polymorph Manipulation , 1997 .
[12] R. Docherty,et al. Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry , 1997 .
[13] Alfons Grunenberg. Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe , 1997 .
[14] G. Stephenson,et al. Formation of isomorphic desolvates: creating a molecular vacuum. , 1998, Journal of pharmaceutical sciences.
[15] Wolfgang Beckmann,et al. Development of a Seeding Technique for the Crystallization of the Metastable A Modification of Abecarnil , 1998 .
[16] Robin K. Harris,et al. NMR study of desmotropy in Irbesartan, a tetrazole-containing pharmaceutical compound , 1998 .
[17] H. Brittain. Polymorphism in Pharmaceutical Solids , 1999 .
[18] G. Desiraju,et al. Pseudopolymorphism: occurrences of hydrogen bonding organic solvents in molecular crystals , 1999 .
[19] Wolfgang Beckmann,et al. Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies , 2000 .
[20] C. A. Mitchell,et al. Crystallization and Polymorphism of Conformationally Flexible Molecules: Problems, Patterns, and Strategies , 2000 .
[21] S. Chemburkar,et al. Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .
[22] A better drug for Alzheimer's , 2000 .
[23] Michael B. Hursthouse,et al. Over one hundred solvates of sulfathiazole , 2001 .
[24] S. Byrn,et al. Chemical reactivity in solid-state pharmaceuticals: formulation implications. , 2001, Advanced drug delivery reviews.
[25] A. Myerson,et al. Effect of Additives on the Transformation Behavior of l-Phenylalanine in Aqueous Solution , 2001 .
[27] Lian Yu. Color Changes Caused by Conformational Polymorphism: Optical-Crystallography, Single-Crystal Spectroscopy, and Computational Chemistry , 2002 .
[28] J. Elguero,et al. Polymorphism vs. Desmotropy: The Cases of 3‐Phenyl‐ and 5‐Phenyl‐ 1H‐pyrazoles and 3‐Phenyl‐1H‐indazole , 2002 .
[29] M. Ticehurst,et al. Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model drug. , 2002, International journal of pharmaceutics.
[30] H. Brittain. Effects of mechanical processing on phase composition. , 2002, Journal of pharmaceutical sciences.
[31] Joel Bernstein,et al. Polymorphism in Molecular Crystals , 2002 .
[32] A. R. Parsons,et al. Automated Measurement of Metastable Zones for Pharmaceutical Compounds , 2003 .
[33] Stephen R. Byrn,et al. Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships , 2003 .
[34] B. K. Hodnett,et al. Inclusion of the Stable Form of a Polymorph within Crystals of Its Metastable Form , 2003 .
[35] Lian Yu,et al. Nucleation of one polymorph by another. , 2003, Journal of the American Chemical Society.
[36] M. Peterson,et al. Crystallization and Transformation of Acetaminophen Trihydrate , 2003 .
[37] W. David,et al. Pressure-induced formation of a solvate of paracetamol. , 2003, Chemical communications.
[38] A. S. Wood,et al. The Chemical Development and Scale-Up of Sampatrilat1 , 2003 .
[39] Michael J Cima,et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.
[40] Lawrence X. Yu,et al. Scientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications , 2003, Pharmaceutical Research.
[41] G. Desiraju. Counterpoint: what's in a name? , 2004 .
[42] Alex M. Chen,et al. Drying an Organic Monohydrate: Crystal Form Instabilities and a Factory-Scale Drying Scheme to Ensure Monohydrate Preservation , 2004 .
[43] K. Seddon. Pseudopolymorph: A Polemic , 2004 .
[44] W. Curatolo,et al. Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.
[45] R. W. Rousseau,et al. Characterization and solid-state transformations of the pseudopolymorphic forms of sodium naproxen , 2004 .
[46] S. Rohani,et al. Improving the filterability and solid density of ranitidine hydrochloride Form 1. , 2004, Journal of pharmaceutical sciences.
[47] S. Black,et al. Increased Chemical Purity Using a Hydrate , 2004 .
[48] J. Bauer,et al. Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.
[49] Abu T M Serajuddin,et al. Trends in solubility of polymorphs. , 2005, Journal of pharmaceutical sciences.
[50] J. Bernstein. And Another Comment on Pseudopolymorphism , 2005 .
[51] Lian Yu,et al. Cross-nucleation between ROY polymorphs. , 2005, Journal of the American Chemical Society.
[52] H. Brittain. Polymorphism and solvatomorphism 2004. , 2005, Profiles of drug substances, excipients, and related methodology.
[53] Saikat Roy,et al. Thermochemical Analysis of Venlafaxine Hydrochloride Polymorphs 1−5† , 2005 .
[54] William Jones,et al. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. , 2005, Journal of pharmaceutical sciences.
[55] Polymorphism in processes of crystallization in solution , 2005 .
[56] David J W Grant,et al. Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.
[57] Rolf Hilfiker,et al. POLYMORPHISM , 1945 .
[58] M. Mitchell,et al. Polymorph and Particle Size Control of PPAR Compounds PF00287586 and AG035029 , 2006 .
[59] P. Dell'orco,et al. A study of variable hydration states in topotecan hydrochloride. , 2006, Journal of pharmaceutical and biomedical analysis.
[60] A. Nangia. Pseudopolymorph: retain this widely accepted term , 2006 .
[61] Martin Müller,et al. Process Development Strategy to Ascertain Reproducible API Polymorph Manufacture , 2006 .
[62] U. Griesser. The Importance of Solvates , 2006 .
[63] G. Desiraju,et al. On the polymorphism of aspirin: crystalline aspirin as intergrowths of two "polymorphic" domains. , 2007, Angewandte Chemie.
[64] N. Rodríguez-Hornedo,et al. Solvent Systems for Crystallization and Polymorph Selection , 2007 .
[65] G. Desiraju,et al. Tautomeric polymorphism in omeprazole. , 2007, Chemical communications.
[66] W. Cabri,et al. Polymorphisms and Patent, Market, and Legal Battles: Cefdinir Case Study , 2007 .
[67] Polymorphic Generation through Solvent Selection: Ranitidine Hydrochloride , 2007 .
[68] W. Motherwell,et al. Organic crystal hydrates : what are the important factors for formation , 2007 .
[69] G. P. Stahly. Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .
[70] H. Brittain,et al. Polymorphism and solvatomorphism 2005. , 2007, Journal of pharmaceutical sciences.
[71] R. K. Jetti,et al. Conformational Polymorphism in Oxybuprocaine Hydrochloride , 2008 .
[72] A. Blackburn,et al. One-solvent polymorph screen of carbamazepine. , 2008, International journal of pharmaceutics.
[73] G. P. Martin,et al. Polymorphic control of inhalation microparticles prepared by crystallization. , 2008, International journal of pharmaceutics.
[74] Yong Cui,et al. Evaluation of hydrate-screening methods. , 2008, Journal of pharmaceutical sciences.
[75] H. Brittain. Polymorphism and solvatomorphism 2006. , 2008, Journal of pharmaceutical sciences.
[76] P. Young,et al. The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfate–Lactose Interactions in DPI Formulations , 2008, Drug development and industrial pharmacy.
[77] Jonathan M Goodman,et al. Polymorph control: past, present and future. , 2008, Drug discovery today.
[78] Crystal polymorphism in antioxidant-metal deactivator 1,2-bis(3,5-di-tert-butyl-4-hydroxyhydrocinnamoyl)hydrazine , 2008 .
[79] M. Jozwiakowski,et al. Alteration of the Solid State of the Drug Substances: Polymorphs, Solvates, and Amorphous Forms , 2008 .
[80] I. Popov,et al. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. , 2008, Journal of pharmaceutical and biomedical analysis.
[81] Darragh Murnane,et al. Crystallization and Crystallinity of Fluticasone Propionate , 2008 .
[82] M. Descamps,et al. Evidence for a New Crystalline Phase of Racemic Ibuprofen , 2008, Pharmaceutical Research.
[83] Crystallisation Design Space: Avoiding a Hydrate in a Water-Based Process , 2009 .
[84] R. Tessadri,et al. Stability of Solvates and Packing Systematics of Nine Crystal Forms of the Antipsychotic Drug Aripiprazole , 2009 .
[85] George Zhou,et al. A Novel Crystallization Methodology To Ensure Isolation of the Most Stable Crystal Form , 2009 .
[86] Geoff G. Z. Zhang,et al. Chapter 2 – Crystalline and Amorphous Solids , 2009 .
[87] F. Puel,et al. Polymorphism in Processes of Crystallization in Solution: A Practical Review , 2009 .
[88] H. Brittain. Polymorphism and solvatomorphism 2007. , 2009, Journal of pharmaceutical sciences.
[89] A Practical Approach for Using Solubility to Design Cooling Crystallisations , 2009 .
[90] M. Al-Omar,et al. Chapter 3 famotidine. , 2009, Profiles of drug substances, excipients, and related methodology.
[91] H. Brittain,et al. Polymorphism and solvatomorphism 2008. , 2010, Journal of pharmaceutical sciences.
[92] R. W. Rousseau,et al. Characterization of Solvates Formed by Sodium Naproxen and an Homologous Series of Alcohols , 2010 .
[93] Keith R Horspool,et al. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.
[94] Process Research and Development of a MTP Inhibitor: Another Case of Disappearing Polymorphs upon Scale-up , 2010 .
[95] Vishal M Sonje,et al. Atorvastatin calcium. , 2010, Profiles of drug substances, excipients, and related methodology.
[96] N. Yagoubi,et al. Polymorphism of Irganox 1076: Discovery of new forms and direct characterization of the polymorphs on a medical device by Raman microspectroscopy. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[97] B. K. Hodnett,et al. Mechanistic Features of Polymorphic Transformations: The Role of Surfaces , 2010 .
[98] S. Velaga,et al. Polymorphism in acesulfame sweetener: structure-property and stability relationships of bending and brittle crystals. , 2010, Chemical communications.
[99] Suciati,et al. Clopidogrel bisulfate. , 2010, Profiles of drug substances, excipients, and related methodology.
[100] Lian Yu. Polymorphism in molecular solids: an extraordinary system of red, orange, and yellow crystals. , 2010, Accounts of chemical research.
[101] E. Kwong,et al. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. , 2010, Journal of medicinal chemistry.
[102] J. Rantanen,et al. Towards effective solid form screening. , 2010, Journal of pharmaceutical sciences.
[103] Development of Drug Substances as Mixture of Polymorphs: Studies to Control Form 3 in Casopitant Mesylate , 2010 .
[104] Motohiro Shiraki. Physical characterization of TRK-720 hydrate, the very late antigen-4 (VLA-4) inhibitor, as a solid form for inhalation: preparation of the hydrate by solvent exchange among its solvates and mechanistical considerations. , 2010, Journal of pharmaceutical sciences.
[105] Christopher Seadeek,et al. A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method. , 2011, Journal of pharmaceutical sciences.